URGN at a glance
UroGen Pharma Ltd. (URGN, SEC CIK 1668243) filed its latest 10-K annual report on March 2, 2026, a 10-Q quarterly report on November 4, 2026, an 8-K current report on November 4, 2026 and Form 4 insider filings as recently as October 9, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), UroGen Pharma Ltd. (URGN) reported revenue of $109.8 million (up 21.4% from FY2024) and a net loss of $153.5 million. Diluted EPS was -$3.19.
- As of September 30, 2026, 27 institutional investment managers tracked by SignalX reported holding UroGen Pharma Ltd. (URGN) shares worth $451.3 million in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by Degnan Chris on October 8, 2026 of 2,202 shares at $36.69 per share.
- In the last 90 days, URGN insiders reported 0 open-market purchases ($0) and 3 open-market sales ($183K) on Form 4, a net sale of $183K.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $109.8M
- +21.4% vs prior year
- Insiders · 90 days
- 0 buys · 3 sells
- Net −$183K
- 13F holders
- 27 funds
- $451.3M · +0 vs prior quarter
- Latest 8-K
- Nov 4, 2026
- Item 2.02
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Sep 30, 2026
Management Discussion & Analysis
- Q3 revenue $89.0M vs $27.5M, up $61.5M YoY, driven primarily by Zusduri sales
- Gross margin 91.6% vs 88.1% YoY, operating margin 9.4% vs negative 99.7%
- Zusduri strongest growth driver, $61.5M revenue increase; Jelmyto standalone revenue not disclosed
- Cash and marketable securities $90.5M; operating cash use $93.5M through nine months
- Pharmakon refinancing provided $67.5M financing cash; management expects funding beyond one year, but may need additional capital
Risk Factors
- New tariff exposure: 15% U.S. tariff on imported mitomycin for Zusduri, effective September 29, 2026
- New financing structure: $200.0 million Pharmakon tranche refinanced $125.0 million outstanding debt, with $50.0 million available through June 30, 2027
- Most material operational risk: TAPI currently sole supplier of commercial mitomycin under April 2026 agreement
- Regulatory risk: FDA staffing reductions and policy changes could delay UGN-103 review, targeting June 14, 2027 action date
- Near-term market risk: Zusduri commercialization depends on physician adoption as the first FDA-approved nonsurgical treatment for recurrent low-grade intermediate-risk NMIBC
AI summary of the URGN 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.02: Results of Operations and Financial Condition
- Q3 2026 financial results announced for quarter ended September 30, 2026
- Detailed results and management commentary available in Exhibit 99.1 press release
Item EX-99.1: Item EX-99.1
- ZUSDURI revenue $68.0M, up 35% quarter-over-quarter, with 331 repeat prescribers supporting commercial adoption
- FDA accepted UGN-103 NDA, with PDUFA target date June 14, 2027, creating a potential successor and portfolio expansion
Item 8.01: Other Events
- Exclusive worldwide option for TumoCure and additional SRGel-based products expands UroGen’s oncology pipeline
- SRGel platform targets sustained-release delivery, potentially complementing UroGen’s drug-delivery expertise
Item EX-99.1: Item EX-99.1
- ZUSDURI revenue reached $50.4M, up 73% quarter-over-quarter, signaling rapid launch adoption across 1,444 care sites
- Repeat prescribers rose to 45% from 40%, supporting improving retention and commercial durability
Item 2.02: Results of Operations and Financial Condition
- UroGen announced financial results for the quarter ended June 30, 2026
- Detailed revenue, earnings, cash position and guidance information appears in Exhibit 99.1
AI summaries of URGN 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for URGN
Don't miss the next URGN filing
- Alerts as it files. A push when URGN files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut URGN, by share count.
- Ask anything. An AI agent that reads every URGN filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Degnan Chris | M | Oct 8, 2026 | 4,483 | - |
| Degnan Chris | Sell | Oct 8, 2026 | 2,202 | $36.69 |
| Degnan Chris | M | Oct 8, 2026 | 4,483 | - |
| Smith Jason Drew | Sell | Sep 8, 2026 | 1,519 | $42.54 |
| Schoenberg Mark | Sell | Sep 8, 2026 | 871 | $42.92 |
| Smith Jason Drew | M | Sep 7, 2026 | 3,334 | - |
| Schoenberg Mark | M | Sep 7, 2026 | 1,667 | - |
| Schoenberg Mark | M | Sep 7, 2026 | 1,667 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | $82.7M | $90.4M | $109.8M |
| Gross Profit | - | $81.5M | $97.3M |
| Operating Income | - | -$96.8M | -$124.9M |
| Net Income | - | -$126.9M | -$153.5M |
| Gross Margin | - | 90.2% | 88.7% |
| Op. Margin | - | -107.1% | -113.7% |
| Net Margin | - | -140.4% | -139.8% |
| Balance Sheet | |||
| Total Assets | - | $285.7M | $200.5M |
| Equity | - | -$8.8M | -$105.5M |
| ROE | - | 1441.3% | 145.5% |
| Per Share | |||
| EPS | - | $-2.96 | $-3.19 |
| Cash Flow | |||
| Operating CF | - | -$96.8M | -$162.4M |
| CapEx | $194K | $295K | $289K |
Source: XBRL data in UroGen Pharma Ltd. (URGN)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate URGN share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 27 | $451.3M |
| Q2 2026 | 27 | $412.8M |
| Q1 2026 | 24 | $185.0M |
| Q4 2025 | 25 | $274.2M |
| Q3 2025 | 24 | $260.5M |
| Q2 2025 | 25 | $143.7M |
| Q1 2025 | 19 | $50.0M |
| Q4 2024 | 16 | $33.4M |
- Two Sigma Investments+257.3K (+173%)
- JPMorgan Chase & Co+170.8K (+432%)
- Millennium Management+162.2K (+152%)
- D.E. Shaw & Co+138.1K (+12%)
- AQR Capital Management+134.4K (+90%)
- Morgan Stanley−401.6K (-16%)
- Bank of America Corp−239.9K (-50%)
- BlackRock−93.3K (-3%)
- Renaissance Technologies LLC−55.4K (-79%)
- ARK Investment Management−47.3K (-47%)
- Raymond James Financial+60.1K
- FMR LLC (Fidelity)−197.1K
Source: 13F-HR filings on SEC EDGAR (aggregated from 187 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
URGN filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 8-K | Nov 4, 2026 | - | Analysis | - |
| 10-Q | Nov 4, 2026 | Sep 30, 2026 | Analysis | |
| 4 | Oct 9, 2026 | - | - | - |
| 4 | Sep 9, 2026 | - | - | - |
| 4 | Sep 9, 2026 | - | - | - |
| 4 | Aug 28, 2026 | - | - | - |
| 4 | Aug 24, 2026 | - | - | - |
| 8-K | Aug 20, 2026 | - | Analysis | - |
| 10-Q | Aug 5, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Aug 5, 2026 | - | Analysis | - |
| 4 | Jul 10, 2026 | - | - | - |
| 4 | Jun 24, 2026 | - | - | - |
| 4 | Jun 24, 2026 | - | - | - |
| 4 | Jun 24, 2026 | - | - | - |
| 4 | Jun 24, 2026 | - | - | - |
| 4 | Jun 24, 2026 | - | - | - |
| 4 | Jun 24, 2026 | - | - | - |
| 4 | Jun 24, 2026 | - | - | - |
| 8-K | Jun 23, 2026 | - | Analysis | - |
| 4 | Jun 9, 2026 | - | - | |
| 8-K | Jun 2, 2026 | - | Analysis | |
| 4 | May 27, 2026 | - | - | |
| SC 13G | May 15, 2026 | - | - | |
| 4 | May 11, 2026 | - | - | |
| 10-Q | May 6, 2026 | Mar 31, 2026 | Analysis |
Related Health Care companies
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
- ABEO · ABEONA THERAPEUTICS INC.Pharmaceutical Preparations
- ACAD · ACADIA PHARMACEUTICALS INCPharmaceutical Preparations
- ACRS · Aclaris Therapeutics, Inc.Pharmaceutical Preparations
- ACTU · ACTUATE THERAPEUTICS, INC.Pharmaceutical Preparations
- ADCT · ADC Therapeutics SAPharmaceutical Preparations
URGN SEC filings: frequently asked questions
Are URGN insiders buying or selling?
In the last 90 days, UroGen Pharma Ltd. (URGN) officers, directors and 10% owners reported no open-market purchases and 3 open-market sales worth $182,793 by 3 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold URGN stock?
As of September 30, 2026, the largest UroGen Pharma Ltd. (URGN) holders among the 13F filers tracked by SignalX were BlackRock ($126.3 million), Morgan Stanley ($88.4 million), D.E. Shaw & Co ($52.2 million), State Street Corp ($39.6 million), Goldman Sachs Group ($34.5 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was URGN's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), UroGen Pharma Ltd. (URGN) reported revenue of $109.8 million (up 21.4% from FY2024) and a net loss of $153.5 million. Diluted EPS was -$3.19. The figures come from the XBRL data in the 10-K.
What did URGN report in its latest 8-K?
UroGen Pharma Ltd. (URGN) filed an 8-K on November 4, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q3 2026 financial results announced for quarter ended September 30, 2026.
What are the latest URGN SEC filings?
UroGen Pharma Ltd. (URGN) filed its latest 10-K annual report on March 2, 2026, a 10-Q quarterly report on November 4, 2026, an 8-K current report on November 4, 2026 and a Form 4 insider filing on October 9, 2026.
What is URGN's SEC CIK number?
UroGen Pharma Ltd. (URGN)'s SEC Central Index Key (CIK) is 1668243. EDGAR lists every URGN filing under that number.
Ask anything about URGN
The research agent reads URGN's filings, financials, insider trades and 13F holders, then answers with sources.